Ed Conway (Director)

Contact InformationEdC_29Aug2014
UBC Centre for Blood Research, Director
Life Sciences Centre
#4306, 2350 Health Sciences Mall
Vancouver, BC, Canada V6T 1Z3
Tel +1-604-822-4252
Fax +1-604-822-7742
Cell +1-778-960-7617

Current Positions

  • Director, Centre for Blood Research
  • Professor of Medicine, University of British Columbia
  • Canada Research Chair in Endothelial Cell Biology
  • CSL-Behring Research Chair
  • Staff Physician, Division of Hematology, Department of Medicine, VCH
  • Adjunct Scientist, Canadian Blood Services
  • Member – Experimental Medicine, Pathology and Laboratory Medicine

Research Interests

Defining the molecular links between coagulation and innate immunity

Throughout evolution, organisms have developed means to simultaneously contain wounds by limiting bleeding with clot formation and fighting pathogens, thereby enabling rapid healing. Disease emerges when there is unchecked activation of the innate immune and/or coagulation responses. Indeed, simultaneous excess coagulation and innate immune responses are evident in numerous diseases, including, for example, atherosclerosis, stroke, coronary heart disease and diabetes, as well as organ ischemia-reperfusion, the metabolic syndrome, and other vasculopathic disorders, such as age-related macular degeneration, and hemolytic-uremic syndrome.

With the discovery that common molecular mechanisms regulate coagulation and inflammation, the last decades have seen major progress in identifying the cellular and molecular links. However, there remain major gaps in our knowledge and new discoveries are urgently needed for the development of novel strategies to prevent and/or treat cardiovascular disease and stroke. In our lab, we characterize the interplay between coagulation and complement, seeking relevant applications to our discoveries, using pre-clinical and clinical modeling approaches.

The perplexing story of the “tumor endothelial marker”, endosialin (CD248)

Endosialin (CD248) was originally identified as a tumor endothelial marker, but is now recognized to be expressed on the surface of activated stromal cells. This multi-domain glycoprotein is only expressed under pathologic conditions. Mice that lack CD248 are less sensitive to pro-inflammatory and oncogenic stimuli. We have determined that the cytoplasmic domain of CD248 modulates intracellular signals that promote tumor growth and inflammation. Ongoing studies are designed to identify molecular mechanisms by which CD248 functions, the protein partners with which CD248 interacts, and the wider impact of changes in expression of CD248. The findings may provide novel avenues for therapeutic targeting.

Selected Publications

  1. Yang CX, Singh A, Kim YW, Conway EM, Carlsten C, Tebbutt Diagnosis of Western Red Cedar Asthma Using a Blood-based Gene Expression Biomarker Panel. American Journal of Respiratory and Critical Care Medicine. 2017 Dec 15;196(12). doi: 10.1164/rccm.201608-1740LE
  2. Pang SS, Wijeyewickrema LC, Hor L, Tan S, Lameignere E, Conway EM, Blom AM, Mohlin FC, Liu X, Payne RJ, Whisstock JC, Pike The Structural Basis for Complement Inhibition by Gigastasin, a Protease Inhibitor from the Giant Amazon Leech. The Journal of Immunology. 2017 Dec 1;199(11):3883-38891. doi: 10.4049/jimmunol.1700158
  3. Foley JH, Walton BL, Aleman MM, O’Byrne AM, Lei V, Harrasser M, Foley KA, Wolberg AS, Conway EM. Complement Activation in Arterial and Venous Thrombosis Is Mediated by Plasmin. EBioMedicine. 2016 Feb;5:175-182. doi: 1016/j.ebiom.2016.02.011
  4. Foley JH, Peterson, EA, Lei V, Wan LW, Krisinger MJ, Conway EM. Interplay between fibrinolysis and complement: Plasmin cleavage of iC3b modulates immune responses. Journal of Thrombosis and Haemostasis. 2015 April;13(4):610-618. doi: 1111/jth.12837
  5. Herzog, C, Lorenz, A, Gillmann, HJ, Chowdhury, A, Larmann, J, Harendza, T, Echtermeyer, F, Müller, M, Schmitz, M, Stypmann, J, Seidler, DG, Damm, M, Stehr, SN, Koch, T, Wollert, KC, Conway, EM, Theilmeier, G. Thrombomodulin’s lectin-like domain reduces myocardial damage by interfering with HMGB1-mediated TLR2 signalling. Cardiovascular Research. 2014 Mar 1;101(3):400-410. doi: 1093/cvr/cvt275
  6. Bellac CL, Dufour A, Krisinger M, Loonchanta A, Starr AE, auf dem Keller U, Lange PF, Goebeler V, Kappelhoff RG, Butler GS, Burtnick LD, Conway EM, Roberts CR, Overall CM. Macrophage Matrix Metalloproteinase-12 Dampens Inflammation and Neutrophil Recruitment in Arthritis: Pleiotropic Roles Revealed by TAILS Proteomics. Cell Reports. 2014;S2211-1247(14)00774-8. PMID: 25310974
  7. Yu K, Lai BFL, Foley JH, Krisinger MJ, Conway EM, Kizhakkedathu JN. Modulation of Complement Activation and Amplification on Nanoparticle Surfaces by Glycopolymer Conformation and Chemistry. American Chem Society (ACS) Nano. 2014 Aug 26;8(8):7687-703
  8. Fukuda S, Hoggatt J, Singh P, Abe M, Speth JM, Hu P, Conway EM, Nucifora G, Yamaguchi S, Pelus LM. Survivin Modulates Genes with Divergent Molecular Functions and Regulates Proliferation of Hematopoietic Stem Cells through Evi-1. Leukemia. 2014 Jun. In Press. PMID: 24903482
  9. Cassis P, Solini S, Azzollini B, Aiello S, Rocchetta F, Conti S, Novelli R, Gagliardini E, Mister M, Rapezzi S, Rapezzi F, Benigni A, Remuzzi G, Conway EM, Noris M. An unanticipated role for survivin in organ transplant damage. American J Transplant. (USA) 2014 May;14(5):1046-60. PMID: 24731002
  10. Kager LM, Wiersinga WJ, Roelofs JJTH, Stroo I, Achouiti A, Conway EM, van ‘t Veer C, van der Poll T. Mice lacking the lectin-like domain of thrombomodulin are protected against Gram-negative sepsis (melioidosis). Critical Care Medicine. 2014 Mar;42(3):e221-30.
  11. Suresh Babu S, Valdez Y, Xu A, O’Byrne, Calvo F, Lei V, Conway EM. TGFb-mediated suppression of CD248 via canonical Smad-dependent signaling pathays is uncoupled in cancer cells. BMC Cancer. 2014 Feb 20;14(1):113. PMID: 24555435
  12. Wat JM, Foley JH, Krisinger MJ, Ocariza LM, Lei V, Wasney GA, Lameignere E, Strynadka NC, Smith SA, Morrissey JH, Conway EM. Polyphosphate suppresses complement via the terminal pathway. Blood. 2014 Jan 30;123(5):768-76.
  13. Iscru E, Ahmed T, Coremans V, Bozzi Y, Caleo M,Conway EM, D’Hooge R, Balschun D. Loss of survivin in neural precursor cells results in impaired long-term potentiation in the dentate gyrus and CA1 region. Neuroscience. 2013;231:413-419.
  14. Foley JH, Conway EM. Gas6 gains entry into the coagulation cascade. Blood. 2013;121(4):570-1.
  15. Hageman S, Wohlschlaeger J, Bertram S, Levkau B, Musacchio A, Conway EM, Moellmann D, Kneiseler G, Pless-Petig G, Lorenz K, Sitec B, Baba HA. Loss of survivin influences liver regeneration due to impaired Aurora B function. Cell Death and Differentiation. 2013. In Press. PMID: 2351907
  16. Gang EJ, Hsieh Y-T, Pham J, Zhao Y, Nguyen C, Huantes S, Park E, Naing K,1 Klemm L, Swaminathan S, Conway EM, Pelus L, Crispino J, Mullighan C, MacMillan M, Müschen M, Kahn M, Kim Y-M. Small molecule inhibition of CBP/catenin interactions eliminates drug resistant clones in acute lymphoblastic leukemia. Oncogene. 2014 Apr 24;33(17):2169-78. PMID: 23728349
  17. Chen J, Chen J-K, Conway EM, Harris RC. Survivin mediates recovery of renal proximal tubule epithelial cells following acute kidney injury. J American Society of Nephrology. 2013 Dec;24(12):2023-33. PMID: 23949800
  18. Adisetiyo H, Liang M, Liao C-P, Aycock-Williams A, Cohen MB, Xu S, Neamati N, Conway EM,Cheng C-Y, Nikitin AY, Roy-Burman P. Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma. PLOS One. 2013 Jul 31;8(7):e69484. PMID: 23936028
  19. Li D, Cen J, Conway EM, Ji Y, Hui L. Hepatic loss of Survivin impairs liver development and promotes expansion of hepatic progenitor cells. Hepatology 2013;58(6):2109-21. PMID: 23813590
  20. Foubert K, Breynaert A, Theunis M, Van Den Bossche R, De Meyer GR, Van Daele A, Faizal A, Goossens A, Geelen D, Conway EM, Vlietinck A, Pieters L, Apers S. Evaluation of the anti-angiogenic activity of saponins from Maesa lanceolata by different assays.Nature Prod Communications. 2012;7(9):1149-54
  21. Wang H, Vinnikov I, He T, Zhou Q, Shahzad K, Ranjan S, Wolter J, Kashif M, Oh J, Kirschfink M, Bierhaus A, Nawroth P,Conway EM, Madhusudhan T, Isermann B.  The lectin-like domain of thrombomodulin ameliorates complement dependent diabetic nephropathy. Thromb Haemost. 2012;108(6):1141-53.
  22. Iscru E, Ahmed T, Coremans V, Bozzi Y, Caleo M,Conway EM, D’Hooge R, Balschun D. Loss of survivin in neural precursor cells results in impaired long-term potentiation in the dentate gyrus and CA1 region. Neuroscience. 2012;231:413-419.
  23. Zoja C, Locatelli M, Pagani C, Corna D, Isermann B, Remuzzi G, Conway EM, Noris M. Lack of the lectin-like domain of thrombomodulin worsens shiga toxin-associated HUS in mice.  J. Immunology. 2012;189(7):3661-8.
  24. Schouten M, de Boer JD, van t Veer C, Roelofs JJTH, Meijers JCM, Levi MM,Conway EM, van der Poll T. The lectin-like domain of thrombomodulin hampers host defense in pneumoccoccal pneumonia. Eur Resp J. 2012 Aug 30.
  25. Krisinger M, Goebeler V, Lu Z, Meixner SC, Myles T, Pryzdial ELG, Conway EM. Revising the terminal complement pathway: Thrombin generates previously unidentified C5 products which augment lytic activity. Blood. 2012;120(8):1717-25.
  26. Conway EM.  Thrombomodulin and its role in inflammation.  Seminars Immunopath. 2012;34(1):107-125.
  27. Valdez Y, Maia M, Conway EM. CD248: Reviewing its role in health and disease.  Curr Drug Targets. 2012 Mar;13(3):432-439.
  28. Conway EM. The Type XIV family of C-type lectin-like domain (CTLD) containing proteins.  Curr Drug Targets. 2012 Mar;13(3):409-410.


  • Ph.D. (Biomedical Sciences), University of Leuven (KUL), Belgium, 2006
  • M.B.A., Heriot Watt University, Scotland, 2004
  • FACP, Harvard University, Boston, 1984
  • FRCP(C), University of Toronto, 1984
  • M.D., University of Toronto, 1979
  • B.A.Sc. (Electrical Engineering), University of Toronto, 1975